Martin Ingelsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/223113/publications.pdf

Version: 2024-02-01

156 papers	20,119 citations	22132 59 h-index	13365 130 g-index
167 all docs	167 docs citations	167 times ranked	27487 citing authors

#	Article	IF	Citations
1	Phosphorylated Î±-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. Brain, 2023, 146, 1065-1074.	3.7	18
2	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimer's Research and Therapy, 2022, 14, 22.	3.0	5
3	In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology, 2022, 208, 108985.	2.0	23
4	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimerâ€™s disease and frontotemporal dementia. BMC Genomics, 2022, 23, 99.	1.2	7
5	CRISPR-Cas9 treatment partially restores amyloid-Î² 42/40 in human fibroblasts with the Alzheimerâ€™s disease PSEN1 M146L mutation. Molecular Therapy - Nucleic Acids, 2022, 28, 450-461.	2.3	13
6	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
7	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nature Genetics, 2022, 54, 560-572.	9.4	250
8	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
9	Modeling Parkinson's diseaseâ€related symptoms in alphaâ€synuclein overexpressing mice. Brain and Behavior, 2022, 12, .	1.0	8
10	Reduction of Î±SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics, 2022, 14, 1412.	2.0	12
11	The existence of AÎ² strains and their potential for driving phenotypic heterogeneity in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
12	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimerâ€™s disease variants: AÎ²PParc and PSEN1DE9. Molecular Psychiatry, 2021, 26, 5609-5619.	4.1	16
13	Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 46.	2.4	14
14	Life-Time Covariation of Major Cardiovascular Diseases. Circulation Genomic and Precision Medicine, 2021, 14, e002963.	1.6	5
15	Astroglial tracer BU99008 detects multiple binding sites in Alzheimerâ€™s disease brain. Molecular Psychiatry, 2021, 26, 5833-5847.	4.1	39
16	Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cellular and Molecular Life Sciences, 2021, 78, 4019-4033.	2.4	54
17	Different Inflammatory Signatures in Alzheimerâ€™s Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	1.2	18
18	Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice. Neurobiology of Aging, 2021, 101, 207-220.	1.5	11

#	Article	IF	Citations
19	Differential DNA Methylation of the Genes for Amyloid Precursor Protein, Tau, and Neurofilaments in Human Traumatic Brain Injury. Journal of Neurotrauma, 2021, 38, 1679-1688.	1.7	18
20	Multiâ€cohort profiling reveals elevated CSF levels of brainâ€enriched proteins in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470.	1.7	19
21	Crosstalk between astrocytes and microglia results in increased degradation of Î±-synuclein and amyloid-Î² aggregates. Journal of Neuroinflammation, 2021, 18, 124.	3.1	81
22	Visualization of early oligomeric Î±â€synuclein pathology and its impact on the dopaminergic system in the (Thyâ€1)â€h[A30P]Î±â€syn transgenic mouse model. Journal of Neuroscience Research, 2021, 99, 2525-2539.	1.3	8
23	Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. Scientific Reports, 2021, 11, 15160.	1.6	23
24	The Uppsala APP deletion causes early onset autosomal dominant Alzheimerâ€™s disease by altering APP processing and increasing amyloid Î² fibril formation. Science Translational Medicine, 2021, 13, .	5.8	23
25	Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart, 2021, 8, e001735.	0.9	14
26	In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease. NeuroImage, 2021, 239, 118302.	2.1	19
27	ABBV-0805, a novel antibody selective for soluble aggregated Î±-synuclein, prolongs lifespan and prevents buildup of Î±-synuclein pathology in mouse models of Parkinson's disease. Neurobiology of Disease, 2021, 161, 105543.	2.1	24
28	Largeâ€Scale Plasma Protein Profiling of Incident Myocardial Infarction, Ischemic Stroke, and Heart Failure. Journal of the American Heart Association, 2021, 10, e023330.	1.6	14
29	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant AÄŸPParc Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5471-5471.	4.1	0
30	Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals. European Journal of Human Genetics, 2020, 28, 349-357.	1.4	47
31	Torque teno virus viral load is related to age, CMV infection and HLA type but not to Alzheimer's disease. PLoS ONE, 2020, 15, e0227670.	1.1	9
32	Î±-Synuclein strains target distinct brain regions and cell types. Nature Neuroscience, 2020, 23, 21-31.	7.1	195
33	Dual-Task Tests Predict Conversion to Dementiaâ€”A Prospective Memory-Clinic-Based Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 8129.	1.2	8
34	Extracellular vesicles from amyloid-Î² exposed cell cultures induce severe dysfunction in cortical neurons. Scientific Reports, 2020, 10, 19656.	1.6	28
35	Dual-task tests discriminate between dementia, mild cognitive impairment, subjective cognitive impairment, and healthy controls â€“ a cross-sectional cohort study. BMC Geriatrics, 2020, 20, 258.	1.1	33
36	Self-reported difficulty initiating sleep and early morning awakenings are associated with nocturnal diastolic non-dipping in older white Swedish men. Scientific Reports, 2020, 10, 13355.	1.6	2

#	Article	IF	Citations
37	Timed Up-and-Go Dual-Task Testing in the Assessment of Cognitive Function: A Mixed Methods Observational Study for Development of the UDDGait Protocol. International Journal of Environmental Research and Public Health, 2020, 17, 1715.	1.2	18
38	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Translational Neurodegeneration, 2020, 9, 27.	3.6	23
39	Risk factors for subarachnoid haemorrhage: a nationwide cohort of 950Â000 adults. International Journal of Epidemiology, 2019, 48, 2018-2025.	0.9	21
40	High levels of AAV vector integration into CRISPR-induced DNA breaks. Nature Communications, 2019, 10, 4439.	5.8	257
41	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	2.4	32
42	Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer's disease and healthy subjects. Analytical Methods, 2019, 11, 3331-3340.	1.3	7
43	Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2019, 71, S75-S83.	1.2	27
44	Antibodies against alphaâ€synuclein: tools and therapies. Journal of Neurochemistry, 2019, 150, 612-625.	2.1	53
45	AÎ² and tau prion-like activities decline with longevity in the Alzheimerâ€™s disease human brain. Science Translational Medicine, 2019, 11, .	5.8	96
46	Binding of Î±-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes. Acta Neuropathologica, 2019, 138, 23-47.	3.9	56
47	Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. Journal of Neuroimmunology, 2019, 332, 31-36.	1.1	7
48	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
49	Genetic predisposition to mosaic Y chromosome loss in blood. Nature, 2019, 575, 652-657.	13.7	198
50	Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet, The, 2019, 394, 2173-2183.	6.3	177
51	Improved Differential Diagnosis of Alzheimerâ€™s Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2019, 67, 639-651.	1.2	32
52	Mosaic loss of chromosome Y in leukocytes matters. Nature Genetics, 2019, 51, 4-7.	9.4	47
53	Early fine motor impairment and behavioral dysfunction in (Thyâ€1)â€h[A30P] alphaâ€synuclein mice. Brain and Behavior, 2018, 8, e00915.	1.0	34
54	Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nature Genetics, 2018, 50, 559-571.	9.4	356

#	Article	IF	Citations
55	Structural heterogeneity and intersubject variability of AÎ² in familial and sporadic Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E782-E791.	3.3	105
56	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimerâ€™s Disease. Molecular Therapy - Nucleic Acids, 2018, 11, 429-440.	2.3	116
57	Rapid amyloidâ€Î² oligomer and protofibril accumulation in traumatic brain injury. Brain Pathology, 2018, 28, 451-462.	2.1	31
58	Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology. Neuropharmacology, 2018, 128, 482-491.	2.0	29
59	Secretion and Uptake of Î±-Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology, 2018, 38, 1539-1550.	1.7	79
60	Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nature Genetics, 2018, 50, 1505-1513.	9.4	1,331
61	Efficient clearance of AÎ² protofibrils in AÎ²PP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimer's Research and Therapy, 2018, 10, 49.	3.0	49
62	In Situ Proximity Ligation Assay Reveals Co-Localization of Alpha-Synuclein and SNARE Proteins in Murine Primary Neurons. Frontiers in Neurology, 2018, 9, 180.	1.1	24
63	Alzheimerâ€™s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathologica, 2018, 136, 41-56.	3.9	334
64	Generation and Characterization of Stable Î±-Synuclein Oligomers. Methods in Molecular Biology, 2018, 1779, 61-71.	0.4	3
65	Cellular Uptake of Î±-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of Î±-Synuclein and Mediated via FcÎ³ Receptors. Cellular and Molecular Neurobiology, 2017, 37, 121-131.	1.7	39
66	Mapping of Surface-Exposed Epitopes of In Vitro and In Vivo Aggregated Species of Alpha-Synuclein. Cellular and Molecular Neurobiology, 2017, 37, 1217-1226.	1.7	8
67	Stability of Proteins in Dried Blood Spot Biobanks. Molecular and Cellular Proteomics, 2017, 16, 1286-1296.	2.5	81
68	Extensive uptake of Î±-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Molecular and Cellular Neurosciences, 2017, 82, 143-156.	1.0	152
69	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
70	Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes. Journal of Neuroscience, 2017, 37, 11835-11853.	1.7	196
71	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
72	Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways. Free Radical Biology and Medicine, 2017, 110, 421-431.	1.3	16

#	Article	IF	Citations
73	Increased Release of Apolipoprotein E in Extracellular Vesicles Following Amyloid-Î² Protofibril Exposure of Neuroglial Co-Cultures. Journal of Alzheimer's Disease, 2017, 60, 305-321.	1.2	44
74	Decreased HHV-6 IgG in Alzheimerâ€™s Disease. Frontiers in Neurology, 2017, 8, 40.	1.1	20
75	Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes. Journal of Neuroinflammation, 2017, 14, 241.	3.1	35
76	Alpha-Synuclein Oligomersâ€”Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. Frontiers in Neuroscience, 2016, 10, 408.	1.4	288
77	Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to Lysosomes. PLoS ONE, 2016, 11, e0168700.	1.1	61
78	Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimerâ€™s Disease Brain. Journal of Alzheimer's Disease, 2016, 54, 1671-1686.	1.2	22
79	567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease. Molecular Therapy, 2016, 24, S226-S227.	3.7	8
80	Deposition of C-terminally truncated AÎ² species AÎ²37 and AÎ²39 in Alzheimerâ€™s disease and transgenic mouse models. Acta Neuropathologica Communications, 2016, 4, 24.	2.4	29
81	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. American Journal of Human Genetics, 2016, 98, 1208-1219.	2.6	164
82	Human Traumatic Brain Injury Results in Oligodendrocyte Death and Increases the Number of Oligodendrocyte Progenitor Cells. Journal of Neuropathology and Experimental Neurology, 2016, 75, 503-515.	0.9	51
83	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253.	0.8	64
84	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	2.8	56
85	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 22.	3.0	39
86	Î±-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cellular and Molecular Neurobiology, 2016, 36, 437-448.	1.7	53
87	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
88	Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease. PLoS ONE, 2016, 11, e0150672.	1.1	77
89	InÂVivo Seeding and Cross-Seeding of Localized Amyloidosis. American Journal of Pathology, 2015, 185, 834-846.	1.9	235
90	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254

#	Article	IF	Citations
91	Changes in secondary structure of Î±-synuclein during oligomerization induced by reactive aldehydes. Biochemical and Biophysical Research Communications, 2015, 464, 336-341.	1.0	18
92	Reduced plasma desmosterolâ€toâ€cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 67-74.	1.2	8
93	Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins. Cell Reports, 2015, 11, 1134-1146.	2.9	88
94	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
95	Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83.	6.0	163
96	Micellar extraction possesses a new advantage for the analysis of Alzheimerâ€™s disease brain proteome. Analytical and Bioanalytical Chemistry, 2015, 407, 1041-1057.	1.9	6
97	Increased Inflammatory Response in Cytomegalovirus Seropositive Patients with Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e96779.	1.1	41
98	AÎ²38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models. Journal of Alzheimer's Disease, 2014, 39, 871-881.	1.2	25
99	Immunotherapy targeting Î±-synuclein, with relevance for future treatment of Parkinsonâ€™s disease and other Lewy body disorders. Immunotherapy, 2014, 6, 141-153.	1.0	48
100	The amyloid-Î² degradation pattern in plasmaâ€"A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters, 2014, 573, 7-12.	1.0	62
101	Serial propagation of distinct strains of Aβ prions from Alzheimerâ€™s disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10323-10328.	3.3	247
102	Abundance of AÎ²5-xlike immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 13.	4.4	19
103	Quantification of the Brain Proteome in Alzheimerâ€™s Disease Using Multiplexed Mass Spectrometry. Journal of Proteome Research, 2014, 13, 2056-2068.	1.8	85
104	Immunotherapy targeting Î±-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] Î±-synuclein mice. Neurobiology of Disease, 2014, 69, 134-143.	2.1	117
105	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
106	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
107	Off-pathwayÎ±-synuclein oligomers seem to alterÎ±-synuclein turnover in a cell model but lack seeding capabilityin vivo. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 233-244.	1.4	22
108	Monoclonal antibodies selective for Î±â€synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and Î±â€synuclein transgenic mice with the diseaseâ€causing A30P mutation. Journal of Neurochemistry, 2013, 126, 131-144.	2.1	77

#	Article	IF	Citations
109	The Arctic AÎ²PP mutation leads to Alzheimerâ€™s disease pathology with highly variable topographic deposition of differentially truncated AÎ². Acta Neuropathologica Communications, 2013, 1, 60.	2.4	38
110	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimerâ€™s Disease Patients Alter Calcium Homeostasis. PLoS ONE, 2013, 8, e74203.	1.1	26
111	Decreased Proportion of Cytomegalovirus Specific CD8 T-Cells but No Signs of General Immunosenescence in Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e77921.	1.1	21
112	Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid-Î² precursor protein. Neurobiology of Aging, 2012, 33, 732-743.	1.5	14
113	The Arctic amyloid-Î² precursor protein (AÎ²PP) mutation results in distinct plaques and accumulation of N- and C-truncated AÎ². Neurobiology of Aging, 2012, 33, 1010.e1-1010.e13.	1.5	31
114	Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation. Journal of Neuroscience, 2012, 32, 11750-11762.	1.7	228
115	Large Aggregates Are the Major Soluble AÎ² Species in AD Brain Fractionated with Density Gradient Ultracentrifugation. PLoS ONE, 2012, 7, e32014.	1.1	85
116	Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. American Journal of Human Genetics, 2012, 90, 217-228.	2.6	168
117	Gelsolin co-occurs with Lewy bodies in vivo and accelerates Î±-synuclein aggregation in vitro. Biochemical and Biophysical Research Communications, 2011, 412, 32-38.	1.0	12
118	Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls. Journal of Alzheimer's Disease, 2011, 22, 1223-1230.	1.2	68
119	The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of Î±-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radical Biology and Medicine, 2011, 50, 428-437.	1.3	121
120	Novel Progranulin Mutation Detected in 2 Patients With FTLD. Alzheimer Disease and Associated Disorders, 2011, 25, 173-178.	0.6	10
121	Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells. PLoS ONE, 2011, 6, e27230.	1.1	61
122	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	1.2	54
123	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. Journal of Alzheimer's Disease, 2010, 20, 509-516.	1.2	347
124	Interference from Heterophilic Antibodies in Amyloid-Î² Oligomer ELISAs. Journal of Alzheimer's Disease, 2010, 21, 1295-1301.	1.2	53
125	Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimerâ€™s disease cases. Journal of Neural Transmission, 2010, 117, 85-96.	1.4	87
126	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86

#	Article	IF	Citations
127	Cystatin C Levels are Positively Correlated with both AÎ²42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. Journal of Alzheimer's Disease, 2010, 21, 471-478.	1.2	25
128	Identification of Low Molecular Weight Pyroglutamate AÎ² Oligomers in Alzheimer Disease. Journal of Biological Chemistry, 2010, 285, 41517-41524.	1.6	91
129	CALHM1 P86L polymorphism does not alter amyloid-Î² or tau in cerebrospinal fluid. Neuroscience Letters, 2010, 469, 265-267.	1.0	11
130	The Alzheimer's Disease-Associated Amyloid Î²-Protein Is an Antimicrobial Peptide. PLoS ONE, 2010, 5, e9505.	1.1	868
131	Rapid Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the <i>APOE </i>Îµ<i>4</i>/Îµ<i>4</i> Genotype. Dementia and Geriatric Cognitive Disorders, 2009, 27, 458-464.	0.7	119
132	Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. Neurogenetics, 2009, 10, 27-34.	0.7	16
133	The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links Î±-synuclein causing rapid formation of stable oligomers. Biochemical and Biophysical Research Communications, 2009, 378, 872-876.	1.0	37
134	A highly insoluble state of AÎ² similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiology of Aging, 2009, 30, 1393-1405.	1.5	79
135	Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. European Journal of Human Genetics, 2008, 16, 171-175.	1.4	24
136	Heparan Sulfate Accumulation with AÎ² Deposits in Alzheimer's Disease and Tg2576 Mice is Contributed by Glial Cells. Brain Pathology, 2008, 18, 548-561.	2.1	71
137	No Association between CALHM1 and Alzheimer's Disease Risk. Cell, 2008, 135, 993-994.	13.5	53
138	Plasma Î² Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men. Archives of Neurology, 2008, 65, 256-63.	4.9	100
139	Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease. Archives of Neurology, 2008, 65, 499.	4.9	91
140	Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families. Journal of Biological Chemistry, 2007, 282, 7825-7832.	1.6	89
141	The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neuroscience Letters, 2007, 427, 127-131.	1.0	112
142	Single molecule profiling of tau gene expression in Alzheimerâ€™s disease. Journal of Neurochemistry, 2007, 103, 1228-1236.	2.1	60
143	Expression of APP pathway mRNAs and proteins in Alzheimerâ€™s disease. Brain Research, 2007, 1161, 116-123.	1.1	159
144	Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathologica, 2007, 114, 471-479.	3.9	36

#	Article	IF	Citations
145	Association study of cholesterol-related genes in Alzheimerâ€™s disease. Neurogenetics, 2007, 8, 179-188.	0.7	47
146	Coordinated Expression of Caspase 8, 3 and 7 mRNA in Temporal Cortex of Alzheimer Disease: Relationship to Formic Acid Extractable AÎ²42 Levels. Journal of Neuropathology and Experimental Neurology, 2006, 65, 508-515.	0.9	54
147	Clinical and biochemical correlates of insoluble Î±-synuclein in dementia with Lewy bodies. Acta Neuropathologica, 2006, 111, 101-108.	3.9	55
148	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimerâ€™s disease brain. Acta Neuropathologica, 2006, 112, 439-449.	3.9	41
149	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1058-1066.	0.9	55
150	Family-Based Association between Alzheimer's Disease and Variants inUBQLN1. New England Journal of Medicine, 2005, 352, 884-894.	13.9	232
151	Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 150-157.	1.8	65
152	Transcriptional Up-Regulation and Activation of Initiating Caspases in Experimental Glaucoma. American Journal of Pathology, 2005, 167, 673-681.	1.9	63
153	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimerâ€™s disease. Neuroscience Letters, 2004, 367, 228-231.	1.0	36
154	Genotyping of Apolipoprotein E : Comparative Evaluation of Different Protocols. Current Protocols in Human Genetics, 2003, 38, Unit9.14.	3.5	23
155	Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7081-7086.	3.3	253
156	Disordered proteins in dementia. Annals of Medicine, 2002, 34, 259-271.	1.5	18